DEA Is Quietly Building a Federal Cannabis Supply Chain

Most cannabis operators understand the immediate significance of rescheduling, particularly the elimination of 280E. But moving cannabis to Schedule III does not, by itself, make the existing cannabis industry federally legal.

Controlled substances in Schedule III are still federally regulated. Businesses manufacturing, distributing, or dispensing them need DEA registration and must operate within the federal Controlled Substances Act. It has been interesting to watch the federal government begin creating that pathway for state-licensed medical cannabis businesses.

Inside DEA's Registration Process

DEA opened its medical marijuana dispensary registration portal in April, and the agency has already been conducting on-site inspections and asking applicants detailed questions about their businesses. Marijuana Moment recently obtained and publicly reported a 26-question list being used by DEA’s Rocky Mountain Division with applicants in Colorado. The questions provide an interesting glimpse into how DEA may be thinking about the future structure of the cannabis industry.

One question stands out: DEA asks whether the business expects to order marijuana or marijuana products from other states. It also asks applicants to identify their medical marijuana suppliers, including their DEA registration numbers. Those questions certainly do not mean interstate cannabis commerce has been authorized. Cannabis markets remain siloed within state borders, and state laws themselves create significant barriers to interstate activity. But it is difficult to ignore what DEA appears to be preparing for.

The Pieces of a Federal Supply Chain

DEA has also announced separate registration forms for cultivators, manufacturers, distributors, and laboratories. In other words, the federal government is developing the pieces necessary for an entire federally regulated cannabis supply chain.

This is where the Marijuana Moment article gets particularly interesting. Colorado is a mature market where medical and adult-use cannabis operate side by side, and DEA’s application specifically asks applicants whether their businesses also handle or dispense recreational marijuana.

The current federal process applies to qualifying medical marijuana activities. But it suggests DEA understands that the industry it is beginning to regulate is not a separate pharmaceutical industry operating in isolation. Many businesses seeking federal registration already operate within mixed medical and adult-use markets.

Hypothetically, we could soon see cannabis businesses with federally compliant medical operations existing alongside state-regulated adult-use operations. The same broader company might participate in both markets, with different rules governing different products or transactions. Exactly how DEA, the states, and eventually FDA will draw those lines remains to be seen, but the federal government appears to be trying to integrate with an industry that already exists rather than requiring the industry to start over.

What Interstate Commerce Would Change

If federally registered cultivators, manufacturers, distributors, and dispensaries can eventually transact with one another across state lines, the economics of cannabis could change dramatically. Producers would no longer necessarily need to duplicate cultivation and manufacturing infrastructure in every state. Products could potentially be manufactured where it makes the most economic sense and distributed into other participating markets. Strong regional brands could become national brands. Supply chains could consolidate, production costs could fall, and capital could flow toward the most efficient operators.

There would unquestionably be disruption. Interstate commerce would put significant pressure on inefficient producers and high-cost cultivation markets. Competition and consolidation would accelerate. But these are also characteristics of a maturing national industry.

Federal registration could have consequences beyond the movement of cannabis itself. A cannabis company holding a DEA registration is in a very different position from a company whose operations remain prohibited under federal law. Over time, those federal permissions could influence banking, lending, insurance, institutional investment, mergers and acquisitions, research, and the willingness of larger traditional companies to participate in cannabis.

None of this means nationwide interstate cannabis commerce is imminent. There are still significant federal and state regulatory issues to resolve, and adult-use cannabis remains a separate problem. But cannabis operators should be paying attention to where the industry may be heading and preparing their businesses accordingly.

What Operators Should Be Doing Now

The companies best positioned for the next stage of cannabis will need more than basic compliance accounting. Increased competition, consolidation, lending opportunities, outside investment, and M&A all place greater importance on accurate financial statements, reliable reporting, strong internal controls, and a clear understanding of margins, cash flow, inventory, and operating performance. Clean financials can be the difference between being able to raise capital, obtain financing, complete an acquisition, or successfully sell a business-and missing the opportunity entirely.

That is where Calyx can help. Our Client Accounting and Advisory Services are designed to give cannabis operators cleaner financials, better visibility, and better management decisions. As the industry changes, we can help businesses strengthen their accounting, understand their performance, prepare for financing or M&A, and position themselves to take advantage of the opportunities that may come with a more mature and increasingly federally regulated cannabis market.